




# MEDICINAL PRODUCTS 2023

Oncocyte Corp  
Rank 36 of 48





# MEDICINAL PRODUCTS 2023

Oncocyte Corp  
Rank 36 of 48



The relative strengths and weaknesses of Oncocyte Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Oncocyte Corp compared to the market average is the variable Goodwill, increasing the Economic Capital Ratio by 85% points. The greatest weakness of Oncocyte Corp is the variable Other Net Income, reducing the Economic Capital Ratio by 64% points.

The company's Economic Capital Ratio, given in the ranking table, is -49%, being 44% points below the market average of -5.0%.

Input Variable	Value in 1000 USD
Assets, Current	25,536
Assets, Non-Current	371
General and Administrative Expense	23,893
Goodwill	61,633
Liabilities, Current	12,106
Liabilities, Non-Current	0
Other Assets	12,551
Other Compr. Net Income	2.0
Other Expenses	-12,239
Other Liabilities	48,391
Other Net Income	-54,905
Other Revenues	958
Property, Plant and Equipment, Net	0
Research and Development	7,301

Output Variable	Value in 1000 USD
Liabilities	60,497
Assets	100,091
Expenses	18,955
Revenues	958
Stockholders Equity	39,594
Net Income	-72,902
Comprehensive Net Income	-72,901
Economic Capital Ratio	-49%